Drug Monographs: Afatinib and Obinutuzumab

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

Obinutuzumab

“…It is, however, 10- to 1000-fold less potent in inducing complement-dependent cytotoxicity. 17,21-25…”